Identifying harmful IgA in IgA-related kidney disease
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies
NA · University Hospital, Limoges · NCT07295808
This project will test whether specific forms of IgA in adults with IgA nephropathy or IgA vasculitis cause kidney damage by analyzing blood and biopsy samples.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Limoges (other) |
| Locations | 1 site (Limoges) |
| Trial ID | NCT07295808 on ClinicalTrials.gov |
What this trial studies
The project enrolls adults with IgA nephropathy or IgA vasculitis and control patients undergoing renal biopsy to collect blood and tissue samples. Researchers will isolate and characterize IgA to examine glycosylation patterns, polymerization state, and anti-IgA autoantibodies. Molecular features of circulating IgA will be correlated with biopsy findings to identify forms with nephritogenic potential. Results aim to clarify mechanisms of IgA-driven glomerular injury and suggest biomarkers for recurrence risk after transplantation.
Who should consider this trial
Good fit: Adults aged 18 or older with IgA nephropathy or IgA vasculitis requiring a renal biopsy, plus control patients undergoing renal biopsy for other diseases, are eligible.
Not a fit: Patients who cannot or will not give consent, or who are under legal guardianship or have prohibitive psychological conditions, are excluded and will not participate.
Why it matters
Potential benefit: If successful, this could identify biomarkers that predict disease severity and recurrence and help guide more targeted management strategies.
How similar studies have performed: Prior studies have reported abnormal IgA glycosylation and related autoantibodies in IgA nephropathy, but directly linking specific IgA forms to nephritogenicity remains incompletely proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of interest: all patients with IgA nephropathy or rheumatoid purpura aged 18 years or older whose treatment requires a renal biopsy * Control patients: all patients with a renal disease other than IgA nephropathy or rheumatoid purpura whose treatment requires a renal biopsy Exclusion Criteria: * Patient opposition * Persons under legal guardianship * Persons whose psychological health prevents the collection of non-opposition
Where this trial is running
Limoges
- Chu Limoges — Limoges, France (RECRUITING)
Study contacts
- Study coordinator: Virginie PASCAL, Physician
- Email: virginie.pascal@chu-limoges.fr
- Phone: 05 55 08 71 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Disease, Kidney disease, Immunoglobulin A, Berger's disease